Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume 5

eBook: US $89 Special Offer (PDF + Printed Copy): US $163
Printed Copy: US $119
Library License: US $356
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-981-14-0514-3 (Print)
ISBN: 978-981-14-0515-0 (Online)
Year of Publication: 2019
DOI: 10.2174/97898114051501190501

Introduction

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers.

The fifth volume of the book features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover cancers such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer.

Preface

Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments in various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. The chapters are written by authorities in the field. The contents of this volume represent exciting recent researches on Acute Myeloid Leukemia, Chemotherapy, Gastrointestinal Cancer, Anti-cancer Therapy, Breast Cancer Cells, and Lung Cancer. I hope that the readers will find these reviews valuable and thought provoking so that they may trigger further research in the quest for the new and novel therapies against cancers.

I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), and Mr. Shehzad Naqvi (Editorial Manager Publications) at Bentham Science Publishers.

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
UK

RELATED BOOKS

.Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine.
.Current Advances in Breast Cancer Research: A Molecular Approach.
.Avastin and Malignant Gliomas .
.Cutting Edge Therapies for Cancer in the 21 Century.